Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 20
- 试验地点
- 16
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.
详细描述
PRIMARY OBJECTIVES:
I. To compare the Overall Survival (OS) for patients with Stage III unresectable non-small cell lung cancer treated with or without nivolumab following concurrent chemoradiation.
II. To compare Progression-Free Survival (PFS) according to RECIST 1.1 criteria for patients with Stage III unresectable non-small cell lung cancer treated with or without nivolumab following concurrent chemoradiation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer (NSCLC) with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC 7th edition)
- •History/physical examination within 30 days prior to registration
- •Computed tomography (CT) scan with IV contrast (CT scan without contrast acceptable if IV contrast is medically contraindicated) of the lung and upper abdomen through the adrenal glands within 60 days prior to registration (recommended within 30 days prior to registration)
- •Magnetic resonance imaging (MRI) of the brain with contrast (or CT with contrast if MRI is medically contraindicated) within 60 days prior to registration; note: the use of intravenous contrast is required for the MRI or CT (unless medically contra-indicated).
- •Whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT within 60 days prior to registration; Note: patients do not need to have a separate CT of chest and upper abdomen with contrast if PET/CT imaging includes a high quality CT chest with contrast.
- •Age ≥ 18 years
- •The trial is open to both genders
- •Zubrod Performance status of 0-1
- •Forced Expiratory Volume at one second (FEV1) > 1.2 liters; Diffusion Capacity of Lung for Carbon Monoxide (DLCO) ≥ 50% predicted
- •Patients must be at least 3 weeks from prior thoracotomy (if performed); if prior thoracotomy then measurable disease on imaging must be present
- •Negative serum pregnancy test within three days prior to registration for women of childbearing potential
- •An archived tumor block or punches instead block must be available for submission for programmed death-ligand 1 (PD-L1) analysis. If an archived tumor block sample cannot be shipped for this study, then two 3mm punches from the core needle biopsy blocks may be provided for analysis. Note: core or excisional biopsy is required for this study. Fine needle aspirates (FNA) and cytology specimens are not adequate for PD-L1 analysis.
- •Agreement of women of childbearing potential to use highly effective contraception during receipt of study drug and up to 161 days (23 weeks) from the last dose of nivolumab/placebo and men receiving nivolumab/placebo who are sexually active with women of childbearing potential to use highly effective contraception during receipt of study drug for 31 weeks from the last dose of nivolumab/placebo.
排除标准
- •Definitive clinical or radiological evidence of metastatic disease
- •Prior or current invasive malignancy (except non-melanomatous skin cancer, localized bladder and prostate cancer) unless disease free for a minimum of 2 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
- •Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. For example, patients with prior breast radiotherapy treatments would likely be excluded.
- •Prior systemic treatment with and anti-programmed cell death protein 1 (PD1), anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
- •Known immunosuppressive disease, for example HIV infection or history of bone marrow transplant or chronic lymphocytic leukemia (CLL)
- •Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. COPD requiring chronic oral steroid therapy
- •Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- •Transmural myocardial infarction within the last 6 months
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- •History of symptomatic or p previously established interstitial lung disease
- •Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection;
- •History of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components
- •As there is potential for hepatic toxicity with nivolumab, drugs with a predisposition to hepatotoxicity should be used with caution in patients treated with nivolumab-containing regimen
- •Pregnancy, nursing females or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
研究组 & 干预措施
Nivolumab
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
干预措施: Radiation Therapy (RT) (Radiation)
Nivolumab
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
干预措施: Cisplatin (Drug)
Nivolumab
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
干预措施: Etoposide (Drug)
Nivolumab
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
干预措施: Nivolumab (Drug)
Placebo
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
干预措施: Radiation Therapy (RT) (Radiation)
Placebo
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
干预措施: Cisplatin (Drug)
Placebo
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
干预措施: Etoposide (Drug)
Placebo
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
干预措施: Placebo (Other)
结局指标
主要结局
Overall Survival (OS)
时间窗: From registration to study termination. Maximum follow-up was 14.9 months.
Survival time is defined as time from registration to date of death from any cause and was to be estimated by the Kaplan-Meier method. Given the limited follow-up due to early closure and termination of data collection, only the number of patients last reported to be alive at time of study termination is reported and no statistical testing was done.
Progression-Free Survival (PFS)
时间窗: From registration to study termination. Maximum follow-up was 14.9 months.
Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) guideline v1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions at any location. Progression was to be determined by an independent radiology review committee using scans submitted to a central location. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored) and was to be estimated by the Kaplan-Meier method.
次要结局
- Number of Participants With Grade 3+ Adverse Events(From registration to study termination. Maximum follow-up was 14.9 months.)
- Percentage of Participants With Deterioration in Functional Assessment of Cancer Therapy - Trial Outcome Index for Lung Cancer (FACT-TOI) at 15 Months(Baseline and 15 months)
- Overall Survival by PD-L1 Status(From registration to study termination. Maximum follow-up was 14.9 months.)
- Progression-Free Survival by PD-L1 Status(From registration to study termination. Maximum follow-up was 14.9 months.)